Mainz Biomed (MYNZ) said Thursday it signed an exclusive license agreement with Liquid Biosciences to develop a blood-based test for detecting pancreatic cancer using mRNA biomarkers.
The company said the financial terms include a license fee and royalties on potential future revenue without disclosing specific details.
Under the agreement, Mainz Biomed will develop the test using Liquid Biosciences' biomarkers, with an option to acquire exclusive global rights, the company said.
The companies plan to refine the test and prepare for a potential submission to the US Food and Drug Administration, Mainz said.
MYNZ shares were 0.8% higher in recent premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。